Jiangsu Province Centers for Disease Control and Prevention

People's Republic of China

Country: People's Republic of China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.jstd.gov.cn/

Clinical Trials

The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

Phase 1

Completed

Conditions: Adenovirus Type-5 Vectored COVID-19 Vaccine

Interventions: Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine

First Posted Date: 2020-09-29

Last Posted Date: 2022-03-31

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 89

Registration Number: NCT04568811

Locations: 🇨🇳
A rehabilitation centre in Wuhan, Wuhan, Hubei, China

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Biological: Two doses of placebo at the schedule of day 0, 28（high-dose group）
Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Biological: Two doses of placebo at the schedule of day 0, 28（middle-dose group）
Biological: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）

First Posted Date: 2020-08-28

Last Posted Date: 2022-06-01

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 168

Registration Number: NCT04530656

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Phase 1

Completed

Conditions: Polio

Interventions: Biological: sIPV
Biological: Commercialized IPV
Biological: Commercialized sIPV

First Posted Date: 2020-02-11

Last Posted Date: 2020-02-11

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 100

Registration Number: NCT04264598

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)

Phase 1

Completed

Conditions: Polio

Interventions: Biological: sIPV

First Posted Date: 2020-02-11

Last Posted Date: 2020-02-11

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT04264546

Locations: 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China

Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .

Phase 3

Completed

Conditions: Adverse Effect and Immunogenicity of Vaccine

Interventions: Biological: Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)
Biological: Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)

First Posted Date: 2019-06-03

Last Posted Date: 2019-06-03

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 1800

Registration Number: NCT03971370

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Phase 1

Completed

Conditions: Staphylococcus Aureus Infection

Interventions: Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7

First Posted Date: 2019-05-29

Last Posted Date: 2021-03-30

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 144

Registration Number: NCT03966040

Locations: 🇨🇳
Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.

Phase 2

Completed

Conditions: Polio and Post-Polio Syndrome

Interventions: Biological: Three-dose regimen of high dosage investigational sIPV
Biological: Three-dose regimen of medium dosage investigational sIPV
Biological: Three-dose regimen of low dosage investigational sIPV
Biological: Three-dose regimen of commercialized sIPV
Biological: Three-dose regimen of commercialized IPV

First Posted Date: 2019-04-03

Last Posted Date: 2019-04-03

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 600

Registration Number: NCT03902054

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China

Phase 4

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
Biological: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
Biological: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
Biological: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
Biological: The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
Biological: The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor